Ten year's experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue SUPL. S1, 2002, Pages 51-55

  Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PLACEBO; POTASSIUM; ANTIFUNGAL AGENT; LIPOSOME;

ARTICLE; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; MALE; MYCOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; PROSPECTIVE STUDY; RECIPIENT; SWEDEN; UNIVERSITY HOSPITAL; ANTIBIOTIC PROPHYLAXIS; COMPARATIVE STUDY; ECONOMICS; METHODOLOGY; REVIEW; STATISTICS; TRANSPLANTATION;

AMPHOTERICIN B; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTICS, ANTIFUNGAL; HOSPITALS, UNIVERSITY; HUMANS; LIPOSOMES; MYCOSES; SWEDEN; TRANSPLANTATION;

EID: 0036178459     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.suppl_1.51     Document Type: Article

References (14)

1. Variables predicting deep fungal infections in bone marrow transplant recipients
2. Invasive Candida albicans infections in orthotopic liver graft recipients. Incidence and risk-factors
3. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation
4. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients
5. Liposomal amphotericin B (AmBisome): Safety data from phase II/III clinical trial
6. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients
7. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients
8. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients
9. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin
10. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone marrow transplantation
11. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients
12. Lipid formulations of amphotericin B. Less toxicity but at what economic cost?
13. Cost effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses
14. Severe and common side effects of amphotericin B lipid complex (Abelcet)